NEI November 1 - 2025 Supporting materials POSTER: Symptoms of Major Depressive Disorder in Adults That Potentially Benefit From the Digital Therapeutic CT-152 POSTER: Assessment of Efficacy Outcomes Based on Treatment Adherence to Rejoyn (CT-152) in Adults With Major Depressive Disorder POSTER: Effects of adjunctive brexpiprazole on depression and life engagement in patients with noradrenaline-mediated symptoms POSTER: Patient-reported symptom severity and functioning with brexpiprazole in combination with sertraline in adults with post-traumatic stress disorder POSTER: Efficacy of brexpiprazole in combination with sertraline on individual symptoms of post-traumatic stress disorder in adults POSTER: Impact of Centanafadine on Learning Problems in Pediatric Patients With ADHD: Analysis of Conners 3 and Exit Survey Responses POSTER: Adult Responders and Participant-Reported Depressive Symptom Clusters That May Benefit From CT-152 Therapy for Major Depressive Disorder POSTER: Comparison of Caregiver Exit Survey With Efficacy Measures in the Treatment of Attention-Deficit/Hyperactivity Disorder With Centanafadine in a Pediatric Population POSTER: Impact of Centanafadine on Sleep in Adults With ADHD: Safety Assessments Pooled From Two Phase 3 Trials POSTER: Evaluating Changes in Anxiety Symptoms With Rejoyn (CT-152) Among Adult Participants With Major Depressive Disorder and Comorbid Anxiety POSTER: A Prescription Digital Therapeutic, CT-152, for Treating Major Depressive Disorder: Effectiveness and Safety Results of the Mirai Randomized Controlled Trial POSTER: Efficacy of CT-152 for Major Depressive Disorder in Adult Participants With Baseline Anxiety Symptoms and/or Difficulty Sleeping POSTER: Impact of Intrinsic Factors on the Efficacy of Centanafadine in an Adult Population with Attention-Deficit/Hyperactivity Disorder POSTER: Impact of Centanafadine on Executive Functioning in Pediatric Patients With Attention-Deficit/ Hyperactivity Disorder: Analysis of Conners 3 and Exit Survey Responses POSTER: Clinically Meaningful, Caregiver-Rated Improvements in ADHD Symptoms Following 6 Weeks of Centanafadine Treatment in Pediatric Patients With ADHD
